培养阳性呼吸机相关肺炎中FilmArray肺炎检测面板未覆盖细菌的流行病学与预测:一项回顾性多中心分析
该多中心回顾性研究分析了法国12个ICU 2016年1月至2021年3月的385例培养阳性VAP发作(332例患者),评估BioFire® FilmArray® Pneumonia Panel(FAPPP)未覆盖细菌的流行率及相关危险因素。未覆盖病原体见于23%(87/385)的VAP发作,占分离细菌的21%(110/534);最常见为嗜麦芽窄食单胞菌(22%)、Citrobacter koseri和Hafnia alvei。革兰染色与最终培养一致性仅42%。多因素分析显示ICU内抗生素暴露与未覆盖细菌风险增加两倍相关(25.3% vs 12.9%,p=0.042),年龄>70岁与三倍风险增加相关(p=0.027)。作者结论认为仅阳性FAPPP结果可能有助于早期个体化抗生素治疗。
要点
- 培养阳性VAP中23%(87/385)存在FAPPP未覆盖细菌,占分离细菌的21%(110/534),最常见的未覆盖细菌为嗜麦芽窄食单胞菌(22%)。
- 多因素分析显示ICU内抗生素暴露与未覆盖细菌风险增加两倍相关(25.3% vs 12.9%,p=0.042),年龄>70岁与三倍风险增加相关(p=0.027)。
- 多微生物培养阳性VAP发生未覆盖细菌的风险为两倍(47% vs 25%,p<0.001)。
- 48例经验性治疗无效的培养阳性VAP中,最常见细菌为铜绿假单胞菌(22%)、嗜麦芽窄食单胞菌(14%)和阴沟肠杆菌复合群(8%)。
- 67%经验性治疗无效的VAP涉及面板覆盖细菌,其中59%若已知面板结果并根据当前指南可能接受有效经验性抗生素治疗。
适用人群与场景
- 法国12个ICU中2016年1月至2021年3月培养阳性的VAP成人病例,共332例患者、385次VAP发作。
诊断标准与关键阈值
- 未覆盖细菌定义为VAP期间分离出的、未包含在FilmArray面板中、但临床医生在最终抗生素治疗中考虑的细菌种类。
研究设计与关键结果
- 研究类型:多中心回顾性研究,纳入法国12个ICU 2016年1月至2021年3月培养阳性VAP 385次发作(332例患者)。
- 未覆盖病原体见于23%(87/385)的VAP发作,占分离细菌的21%(110/534);排除低致病性细菌后,存在未覆盖细菌的VAP比例为21%。
- 最常见的未覆盖细菌为嗜麦芽窄食单胞菌(22%)、Citrobacter koseri和Hafnia alvei。
- 革兰染色与最终培养一致性差(42%一致)。
- 各ICU之间培养阳性VAP中未覆盖细菌的比例差异显著,范围为12%至37%(p=0.013)。
- 多微生物培养阳性VAP发生未覆盖细菌的风险为两倍(47% vs 25%,p<0.001)。
- 多因素分析中,ICU内抗生素暴露与未覆盖细菌风险增加两倍相关(25.3% vs 12.9%,p=0.042),年龄>70岁与三倍风险增加相关(p=0.027)。
- 48例经验性治疗无效的培养阳性VAP中,最常见细菌为铜绿假单胞菌(22%)、嗜麦芽窄食单胞菌(14%)和阴沟肠杆菌复合群(8%);67%涉及面板覆盖细菌,其中59%若已知面板结果并根据当前指南可能接受有效经验性抗生素治疗。
证据类型、等级与局限
- 证据类型:多中心回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为仅阳性FAPPP结果可能有助于临床医生对VAP进行早期个体化抗生素治疗。
- 培养阳性VAP中未覆盖细菌比例较高,对FAPPP结果的解读需谨慎。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ventilator-associated pneumonia (VAP) is a prevalent nosocomial infection in intensive care units (ICUs) with significant impacts on patient outcomes and healthcare costs. Multiplex PCR could allow for personalized empirical treatment of VAP and optimize antibiotic therapy.
METHODS: This multicenter retrospective study analyzed culture-positive VAP cases from January 2016 to March 2021 across 12 ICUs in France. The prevalence of non-targeted bacteria was evaluated according to the bacterial species included in the BioFire® FilmArray® Pneumonia Panel (FAPPP), and associated risk factors were identified. A non-targeted bacteria was defined as a bacterial species isolated during VAP, not included in the FilmArray panel, but considered by the clinician in the final antibiotic therapy.
RESULTS: Among 332 patients with 385 culture-positive VAP episodes, non-targeted pathogens were observed in 23% of cases (87/385) and represented 21% (110/534) of isolated bacteria (After excluding bacteria with low pathogenicity, the rate of VAP with a non-targeted bacterium was 21%). The most common non-targeted bacteria identified were Stenotrophomonas maltophilia (22%), Citrobacter koseri, and Hafnia alvei. Gram stain results poorly correlated with definitive cultures (42% of concordance). The proportion of culture-positive VAP with non-targeted bacteria varied significantly between ICUs, ranging from 12 to 37%, (p = 0.013). Polymicrobial culture-positive VAP had a twofold higher risk of non-targeted bacteria (47% vs. 25%, p < 0.001). In the multivariate analysis, in-ICU antibiotic exposure was associated with a twofold increased risk of non-targeted bacteria (25.3% vs. 12.9%, p = 0.042), and age over 70 years was associated with a threefold increased risk (p = 0.027). Among the 48 culture-positive VAP cases with ineffective empiric treatment, Pseudomonas aeruginosa (22%), Stenotrophomonas maltophilia (14%), and Enterobacter cloacae complex (8%) were the most frequent bacteria. Additionally, 67% of the culture-positive VAP cases with ineffective empirical antibiotic therapy involved targeted bacteria, of which 59% could have received effective empirical antibiotic therapy if panel results had been available, according to bacterial species identification and current guidelines.
CONCLUSIONS: A significant rate of culture-positive VAP cases with non-targeted bacteria was observed in this study, raising concerns about the interpretation of FAPPP results. Only positive FAPPP results may assist clinicians in the early personalization of antibiotic therapy for VAP.
参考来源
- Berteau F, Kouatchet A, Le Gall Y, et al. Epidemiology and prediction of non-targeted bacteria by the filmarray pneumonia plus panel in culture-positive ventilator-associated pneumonia: a retrospective multicentre analysis. Ann Intensive Care. 2025. PMID: 40293547. doi:10.1186/s13613-025-01468-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。